TA-TMA severity by stratification and risk group
| . | Total . | SR . | HR . | ||
|---|---|---|---|---|---|
| . | . | Prestratification . | Poststratification* . | Prestratification . | Poststratification† . |
| Total TA-TMA Cases | 15/257 | 4/135 | 3/73 | 7/26 | 1/23 |
| Typical vs severe | |||||
| Typical | 7 | 3 | 2 | 1 | 1 |
| Severe‡ | 8 | 1§ | 1 | 6 | 0 |
| . | Total . | SR . | HR . | ||
|---|---|---|---|---|---|
| . | . | Prestratification . | Poststratification* . | Prestratification . | Poststratification† . |
| Total TA-TMA Cases | 15/257 | 4/135 | 3/73 | 7/26 | 1/23 |
| Typical vs severe | |||||
| Typical | 7 | 3 | 2 | 1 | 1 |
| Severe‡ | 8 | 1§ | 1 | 6 | 0 |
No change in clinical practice other than enhanced screening for development of TA-TMA.
HR poststratification patients received prophylaxis with NAC and EPA.
Severe TA-TMA defined as the need for admission to the intensive care unit, surgical drainage of effusions, or dialysis and the presence of gastrointestinal bleeding or neurologic involvement.
This patient was diagnosed retrospectively and did not receive treatment.